Literature DB >> 30806983

25C-NBOMe, a Novel Designer Psychedelic, Induces Neurotoxicity 50 Times More Potent Than Methamphetamine In Vitro.

Peng Xu1,2, Qiyang Qiu2, Haijie Li2, Sicheng Yan2, Mengxiang Yang2, C Benjamin Naman3, Youmei Wang1, Wenhua Zhou2, Haowei Shen4,5, Wei Cui6,7,8.   

Abstract

25C-NBOMe is a designer substituted phenethylamine and a high-potency psychedelic that acts on the 5-HT2A receptor. Although 25C-NBOMe overdoses have been related to several deaths in the USA and Europe, very limited data exists on the in vitro neurotoxicity of 25C-NBOMe. In this study, we found that 25C-NBOMe potently reduced cell viability of SH-SY5Y, PC12, and SN4741 cells, with IC50 values of 89, 78, and 62 μM, respectively. Methamphetamine decreased the cell viability of these cells with IC50 values at millimolar range in the same tests, indicating that 25C-NBOMe is > 50 times more potent than methamphetamine in its ability to reduce viability of SH-SY5Y cells. The neurotoxicity of 25C-NBOMe on SH-SY5Y cells was further confirmed by using fluorescein diacetate/propidium iodide double staining. 25C-NBOMe elevated the expression of phosphorylated extracellular signal-regulated kinase (pERK), but decreased the expression of phosphorylated Akt and phosphorylated Ser9- glycogen synthase kinase 3β (GSK3β) in time- and concentration-dependent manners. Interestingly, either specific GSK3β inhibitors or specific mitogen-activated protein kinase kinase (MEK) inhibitors significantly prevented 25C-NBOMe-induced neurotoxicity in SH-SY5Y cells. These results suggest that 25C-NBOMe unexpectedly produced more potent neurotoxicity than methamphetamine and that the inhibition of the Akt pathway and activation of the ERK cascade might be involved in 25C-NBOMe-induced neurotoxicity. Most importantly, these findings further inform the toxicity of 25C-NBOMe abuse to the central nervous system for public health.

Entities:  

Keywords:  25C-NBOMe; Designer drugs; ERK; GSK3β; Psychedelic; Substituted phenethylamine

Mesh:

Substances:

Year:  2019        PMID: 30806983     DOI: 10.1007/s12640-019-0012-x

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  5 in total

1.  DARK Classics in Chemical Neuroscience: NBOMes.

Authors:  Christian B M Poulie; Anders A Jensen; Adam L Halberstadt; Jesper L Kristensen
Journal:  ACS Chem Neurosci       Date:  2019-11-12       Impact factor: 5.780

2.  The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides.

Authors:  P Mallaroni; N L Mason; F R J Vinckenbosch; J G Ramaekers
Journal:  Psychopharmacology (Berl)       Date:  2022-04-30       Impact factor: 4.415

3.  Neurotoxicological profile of the hallucinogenic compound 25I-NBOMe.

Authors:  Monika Herian; Adam Wojtas; Marzena Maćkowiak; Agnieszka Wawrzczak-Bargiela; Anna Solarz; Agnieszka Bysiek; Katarzyna Madej; Krystyna Gołembiowska
Journal:  Sci Rep       Date:  2022-02-21       Impact factor: 4.379

4.  Human Neuronal Cell Lines as An In Vitro Toxicological Tool for the Evaluation of Novel Psychoactive Substances.

Authors:  Valeria Sogos; Paola Caria; Clara Porcedda; Rafaela Mostallino; Franca Piras; Cristina Miliano; Maria Antonietta De Luca; M Paola Castelli
Journal:  Int J Mol Sci       Date:  2021-06-24       Impact factor: 5.923

Review 5.  Neuronal and peripheral damages induced by synthetic psychoactive substances: an update of recent findings from human and animal studies.

Authors:  Giulia Costa; Maria Antonietta De Luca; Gessica Piras; Jacopo Marongiu; Liana Fattore; Nicola Simola
Journal:  Neural Regen Res       Date:  2020-05       Impact factor: 5.135

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.